2025
Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform
Exarchos A, Bourla A, Kaur M, Schulze K, Maund S, Cao Y, Zhao Y, Williams E, Gaffey S, Zuniga R, Lakhanpal S, Antic V, Doral M, Sy J, Meropol N, Chiang A. Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemporary Clinical Trials Communications 2025, 44: 101446. PMID: 40027276, PMCID: PMC11869879, DOI: 10.1016/j.conctc.2025.101446.Peer-Reviewed Original ResearchCirculating tumor DNAClinico-genomic datasetsRecurrent metastatic non-small cell lung cancerExtensive-stage small-cell lung cancerLung cancerMetastatic non-small cell lung cancerStandard line of therapyCirculating tumor DNA testingSmall-cell lung cancerNon-small cell lung cancerLines of therapyCell lung cancerClinico-genomic databaseSerial blood samplesPre-specified timepointsCommunity-based research sitesTumor DNAPatient cohortClinical dataStage IVGenomic profilingPrognostic biomarkerAcademic centersUS sitesBlood samples
2020
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.
Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.Peer-Reviewed Original ResearchCell lung cancerLung cancerOverall survivalOutcome dataExtensive-stage small-cell lung cancerMetastatic non-small cell lung cancerNon-small cell lung cancerSmall cell lung cancerReal-world clinical outcomesGenomic profilingFirst tumor assessmentFlatiron Health networkTechnology-enabled abstractionLines of therapyMetastatic lung cancerEnd of treatmentWithdrawal of consentClinical data pointsEnd of studyTumor DNA ProfilingAnti-neoplastic treatmentCase report formsTumor tissue samplesBlood genomic profilingElectronic health records
2017
Racial disparities in the use of programmed death-1 checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.Peer-Reviewed Original ResearchDeath-1 checkpoint inhibitorsElectronic health record databaseLines of therapySystemic therapyCheckpoint inhibitorsCancer clinicRacial disparitiesAdvanced non-small cell lung cancerNon-small cell lung cancerMetastatic renal cell carcinomaAnti-PD1 treatmentCell lung cancerRenal cell carcinomaHealth record databaseSignificant racial disparitiesNew cancer drugsSquamous histologyStudy drugReal-world practiceAdvanced melanomaTherapy linesWhite patientsMale sexCell carcinomaLung cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply